Threatened miscarriage is manifested by vaginal bleeding, with or without abdominal pain, while the cervix is closed and the fetus is viable and inside the uterine cavity. Threatened miscarriage is a common complication of pregnancy occurring in 20% of all clinically recognized pregnancies and about half of these will eventually result in pregnancy loss. The goal of this two by two factorial, placebo controlled randomized trial is to determine that two oral medications and their combination, will mostly likely result in live birth in women with threatened miscarriage. We will evaluate the efficacy and safety of Chinese herbal medicine (New "Shoutai Wan", NSTW) and/or oral micronized progesterone (OP) for treating threatened miscarriage in this trial. Our primary outcome of this trial is live birth. We hypothesize that: 1. treatment with NSTW plus OP or OP placebo is more likely to result in live birth than NSTW placebo plus OP or placebo; 2. treatment with OP plus NSTW or NSTW placebo is more likely to result in live birth than OP placebo plus NSTW or NSTW placebo; 3. treatment with combination of NSTW and OP is more likely to result in live birth than combination of NSTW placebo and OP placebo.
The causes of spontaneous miscarriage are diverse and comprise chromosomal, genetic, anatomical, immunological, hormonal, infectious and psychological factors, the other factors contribute to an increased risk include advancing paternal and maternal age and mothers with systemic diseases, such as diabetes or thyroid dysfunction. The incidence is difficult to determine precisely because it occurs very early during a pregnancy and almost 30% of early pregnancy may go unrecognized; the pathogenesis of pregnancy loss in this condition is still remains obscure. Compared with healthy women, the women with threatened miscarriage were found not only to have increased rate of antepartum haemorrhage, prelabour rupture of the membranes, preterm delivery, and intrauterine growth restriction, but also suffer from significant psychological impairment including considerable anxiety and stress, depression, sleep disturbances, anger, and marital disturbances. To date, therapies have limited effectiveness in treating threatened miscarriage and are empirical. Bed rest does not prevent pregnancy loss. Acetaminophen may have some effects on relieving pain only. The most commonly used prescription medication was human chorionic gonadotropin (hCG), maintaining the luteotrophic effects to support continued secretion of estrogen and progesterone, but it's beneficial effects still cannot be verified. Progesterone is another most commonly used standard medication, maintaining the endometrial proliferation and preventing poor decidualization. A number of recent studies in women with threatened miscarriage shown a reduction in pregnancy loss with progesterone treatment. But progestogens are a group of hormones, including both the natural female sex hormone progesterone and the synthetic forms. Micronized progesterone is a kind of progesterone; it is structurally and pharmacologically very similar to natural progesterone and has good oral bioavailability. It is especially suitable for women with threatened miscarriage as it does not have androgenic or oestrogenic effects on the foetus. A recent review of maternal use of micronized progesterone during pregnancy also found no evidence for an increased risk of congenital malformations. However it may only be suitable to treat women with threatened miscarriage who have low progesterone levels due to corpus luteum deficiency at the first trimester of pregnancy. There is no evidence to show the beneficial effects of progesterone to treat threatened miscarriage due to others factors. At the same time, progesterone treatment is also expensive. New or adjuvant treatments that are suitable, readily accessible, affordable, and safe are needed to treat women with threatened miscarriage.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
1,656
Chinese Herbal Medicine (New "Shoutai Wan", one pack twice daily) + Oral Progesterone (100 mg thrice daily)
Chinese Herbal Medicine (New "Shoutai Wan", one pack twice daily) + Oral Progesterone Placebo (100 mg thrice daily)
Chinese Herbal Medicine Placebo (New "Shoutai Wan" placebo, one pack twice daily) + Oral Progesterone (100 mg thrice daily)
Chinese Herbal Medicine Placebo (New "Shoutai Wan" placebo, one pack twice daily) + Oral Progesterone Placebo (100 mg thrice daily)
The First Affiliated Hospital of Anhui University of Chinese Medicine
Hefei, Anhui, China
Guangdong Provincial Hospital of Chinese Medicine
Guangzhou, Guangdong, China
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Da Qing Long Nan Hospital
Daqing, Heilongjiang, China
First Affiliated Hospital, Heilongjiang University of Chinese Medicine
Harbin, Heilongjiang, China
Luoyang Hospital of Traditional Chinese Medicine
Luoyang, Henan, China
The First Affiliated Hospital of Hunan University of Chinese Medicine
Changsha, Hunan, China
Changzhou Hospital of Traditional Chinese Medicine
Changzhou, Jiangsu, China
Suqian Maternity Hospital
Suqian, Jiangsu, China
The People's Hospital of Siyang
Suqian, Jiangsu, China
...and 12 more locations
Live birth
Rate of live birth at or beyond 20 completed weeks' gestation
Time frame: At or beyond 20 completed weeks' gestation
Pregnancy outcome: Ongoing pregnancy
Rate of ongoing pregnancy (beyond 12 weeks' gestation)
Time frame: Beyond 12 weeks' gestation
Pregnancy outcome: Miscarriage during the first trimester
Rate of miscarriage during the first trimester (at or before 12 weeks' gestation)
Time frame: During the first trimester (at or before 12 weeks' gestation)
Pregnancy outcome: Miscarriage during second and third trimesters
Rate of miscarriage during second and third trimesters (beyond 12 weeks' gestation until 20 weeks)
Time frame: During second and third trimesters (beyond 12 weeks' gestation until 20 weeks)
Pregnancy outcome: Termination
Rate of termination at any time during treatment and follow-up period
Time frame: At any time during treatment (up to 2 months) and follow-up period (up to 1 year)
Pregnancy outcome: Stillbirth
Rate of stillbirth (at or beyond 20 weeks' gestation)
Time frame: At or beyond 20 weeks' gestation
Pregnancy outcome: Induced abortion
Rate of induced abortion at any time during treatment and follow-up for any reasons
Time frame: At any time during treatment (up to 2 months) and follow-up period (up to 1 year)
Pregnancy outcome: Gestational age at delivery
Gestational age at delivery (weeks and days)
Time frame: Up to 1 day after delivery
Pregnancy outcome: Preterm birth
Rate of preterm birth (birth beyond 28 week and before 37 completed weeks' gestation (up to and including 36 weeks and 6 days of gestation))
Time frame: Birth before 37 completed weeks' gestation (up to and including 36 weeks and 6 days of gestation)
Pregnancy outcome: Extreme preterm birth
Rate of extreme preterm birth (birth beyond 20 weeks and before 28 completed weeks' gestation (up to and including 27 weeks and 6 days of gestation))
Time frame: Birth beyond 20 weeks and before 28 completed weeks' gestation (up to and including 27 weeks and 6 days of gestation)
Pregnancy outcome: Full-term birth
Rate of full-term birth (at or beyond 37 weeks' gestation, and before 42 weeks' gestation)
Time frame: At or beyond 37 weeks' gestation, and before 42 weeks' gestation
Pregnancy outcome: Post-term birth
Rate of post-term birth (at or beyond 42 weeks' gestation)
Time frame: At or beyond 42 weeks' gestation
Neonatal outcome: Birth weight
Birth weight of neonatal (adjusted for gestational age and sex by Chinese standards)
Time frame: When neonatal is born
Neonatal outcome: Small for gestational age
Rate of small for gestational age when neonatal is born
Time frame: When neonatal is born
Neonatal outcome: Large for gestational age
Rate of large for gestational age when neonatal is born
Time frame: When neonatal is born
Neonatal outcome: Congenital malformation
Rate of congenital malformation
Time frame: At any time during treatment (up to 2 months) and follow-up period (up to 1 year)
Other outcome: Mean score change in TCM Symptom Questionnaire
Mean score change in TCM Symptom Questionnaire from baseline to the end of intervention. The questionnaire covers many dimensions including symptoms (amount of vaginal bleeding, severity of abdominal pain and other general symptoms), emotional factors and so on. The minimum and maximum value are depend on the symptoms of the patient respectively.
Time frame: From date of randomization until the date of end of treatment, assessed up to 2 months
Other outcome: Mean score change in 12-Item Short-Form Health Survey
Mean score change in 12-Item Short-Form Health Survey from baseline to the end of intervention. The minimum value is 0 and the maximum value is 100, and higher scores mean a better outcome.
Time frame: From date of randomization until the date of end of treatment, assessed up to 2 months
Other outcome: Mean score change in Self-Rating Anxiety Scale
Mean score change in Self-Rating Anxiety Scale from baseline to the end of intervention. The minimum value is 20 and the maximum value is 80, and lower scores mean a better outcome.
Time frame: From date of randomization until the date of end of treatment, assessed up to 2 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.